Maven Securities’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-9,800
Closed -$1.01M 1109
2023
Q3
$1.01M Buy
9,800
+3,900
+66% +$435K 0.01% 617
2023
Q2
$717K Sell
5,900
-4,600
-44% -$614K 0.01% 530
2023
Q1
$1.61M Sell
10,500
-2,300
-18% -$379K 0.03% 345
2022
Q4
$2.3M Buy
+12,800
New +$2.09M 0.05% 215
2022
Q2
Sell
-1,000
Closed -$172K 1040
2022
Q1
$172K Buy
+1,000
New +$168K 0.01% 806
2021
Q4
Sell
-1,200
Closed -$465K 1051
2021
Q3
$465K Sell
1,200
-3,800
-76% -$1.4M 0.02% 674
2021
Q2
$1.18M Buy
+5,000
New +$894K 0.05% 382

Other funds holding MRNA

Maven Securities's MRNA Position: Q4 2023 in Review

Maven Securities sold out of Moderna (MRNA) in Q4 2023, closing a stake of 5,769 shares — an estimated $596K sold.

Maven Securities first reported a position in MRNA in Q3 2019 and held it in 8 quarters. The position peaked at $1.53M in Q3 2022. 884 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

  • Maven Securities reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
  • Maven Securities sold 5,769 Moderna shares in Q4 2023, an estimated $596K.
  • Maven Securities first reported a position in Moderna in Q3 2019 and held it in 8 quarters.
  • Maven Securities's Moderna position peaked at $1.53M in Q3 2022.
  • 884 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on Maven Securities's 13F filing for Q4 2023, filed 12 Feb 2024.